Table 4 CSF biomarkers of neuroinflammation in the FTD/FTLD spectrum
From: CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia
|  | Number | CHIT1 all (pg/ml), median (IQR) | CHIT1 WT + Het (pg/ml), median (IQR) | YKL-40 (ng/ml), median (IQR) | GFAP (ng/ml), median (IQR) |
|---|---|---|---|---|---|
Clinical diagnosis | |||||
 bvFTD | 17 | 3178 (2008–6437) | 3877 (2178–6713) | 186 (120–254) | 1.365 (0.784–1.977) |
 PPA | 8 | 2390 (1642–4306) | 2390 (1642–4306) | 228 (138–268) | 1.101 (0.877–1.252) |
 nfvPPA | 6 | 2934 (1657–6597) | 2934 (1657–6597) | 209 (127–273) | 1.054 (0.800–1.373) |
 svPPA | 2 | 1120, 2959 | 1120, 2959 | 205, 272 | 1.016, 1.260 |
 ALS-FTD | 9 | 11,500 (6309–16,048) | 14,900 (6671–16,789) | 290 (228–392) | 0.867 (0.565–1.326) |
 PSP | 23 | 1767 (929–3074) | 1767 (968–3135) | 192 (151–242) | 0.971 (0.463–1.314) |
 CBS | 12 | 1659 (825–4391) | 1659 (1220–5471) | 161 (135–192) | 1.200 (0.687–1.413) |
 FTD + parkinsonism | 3 | 1744, 941, 19,300 | 1744, 941, 19,300 | 176, 154, 134 | 1.577, 0.672, 1.248 |
FTLD proteinopathies | |||||
 FTLD-TAU | 38 | 1766 (987–3237) | 1732 (1092–3237) | 186 (148–225) | 1.002 (0.649–1.324) |
 FTLD-TDP | 34 | 4484 (1930–11,625) | 4575 (1966–12,000) | 209 (134–264) | 1.226 (0.676–1.686) |
 TDP without ALS | 25 | 3120 (1743–6437) | 3149 (1703–6713) | 180 (132–254) | 1.248 (0.784–1.792) |
 TDP with ALS | 9 | 11,500 (6309–16,048) | 14,900 (6671–16,789) | 290 (228–392) | 0.867 (0.565–1.326) |